YMTracker DRIPCalc v2 Launch sale

NEW Our free Dividend Tracker is live — see what your stocks pay you

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

TMDX | NASDAQ

$84.07 $1.34 | 1.62%

SIGNAL:

Signal available — unlock to view

|2026-09-29 |F&G 43 |RSI 43.3

Add to favoritesFavorite

Company Overview:

Market Cap: $2.91B

Trailing PE: 21.6x

FWD PE *: 45.2x

Payout Ratio (TTM): —

52-Week Range: $60.11 - $156.00

* Forward PE is based on street estimates.

7.4 Year TMDX Performance Metrics:

Total Return (with DRIP): 276.0% (19.60% CAGR)

Total Return (no DRIP): 276.0% (19.60% CAGR)

Share Price: 276.0% (19.60% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $37,598

Total Return $ (with DRIP): $27,598

TMDX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

TMDX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

TMDX Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

TMDX - Revenue

TMDX Revenue CAGR:1Y: 20.70%2Y: 28.91%5Y: 87.62%10Y: 0.00%

TMDX - Earnings Per Share (EPS)

TMDX EPS CAGR:1Y: -55.43%2Y: 8.23%5Y: 0.00%10Y: 0.00%

TMDX - Net Income

🔓 See the full chart40% off right now · 7-day free trial

TMDX Net Income CAGR:1Y: -57.94%2Y: 9.73%5Y: 0.00%10Y: 0.00%

TMDX - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

TMDX EBITDA CAGR:1Y: -20.30%2Y: 47.01%5Y: 0.00%10Y: 0.00%

TMDX - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

TMDX Free Cash Flow CAGR:1Y: -87.62%2Y: 128.61%5Y: 0.00%10Y: 0.00%

TMDX - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

TMDX Free Cash Flow / Share CAGR:1Y: -87.86%2Y: 123.73%5Y: 0.00%10Y: 0.00%

TMDX - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

TMDX Operating Income CAGR:1Y: -35.09%2Y: 37.76%5Y: 0.00%10Y: 0.00%

TMDX - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

TMDX Gross Profit CAGR:1Y: 17.20%2Y: 27.93%5Y: 0.00%10Y: 0.00%

TMDX - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

TMDX Shares Outstanding CAGR:1Y: 0.37%2Y: 7.41%5Y: 8.07%10Y: 0.00%

TMDX - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

TMDX Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TMDX - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

TMDX Stock-Based Comp CAGR:1Y: -8.17%2Y: 6.11%5Y: 36.62%10Y: 0.00%

TMDX - Expenses

🔓 See the full chart40% off right now · 7-day free trial

TMDX Expenses CAGR:1Y: -21.85%2Y: -45.37%5Y: 94.77%10Y: 0.00%

TMDX - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

TMDX - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

TMDX - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

TMDX - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

TMDX - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

TMDX - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

TMDX - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

TMDX Revenue CAGR:1Y: 20.70%2Y: 28.91%5Y: 87.62%10Y: 0.00%

TMDX - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

TMDX Revenue CAGR:1Y: 20.70%2Y: 28.91%5Y: 87.62%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

TMDX - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TMDX Actual Revenue CAGR:1Y: 20.70%2Y: 28.91%5Y: 87.62%10Y: 0.00%

TMDX - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TMDX Actual EPS CAGR:1Y: -55.43%2Y: 8.23%5Y: 0.00%10Y: 0.00%

TMDX - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TMDX Actual Net Income CAGR:1Y: -57.94%2Y: 9.73%5Y: 0.00%10Y: 0.00%

TMDX - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TMDX Actual EBITDA CAGR:1Y: -20.30%2Y: 47.01%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

TMDX - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

TMDX Net Profit Margin CAGR:1Y: -65.15%2Y: -14.88%5Y: 0.00%10Y: 0.00%

TMDX - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

TMDX Gross Profit Margin CAGR:1Y: -2.92%2Y: -0.76%5Y: -2.72%10Y: 0.00%

TMDX - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

TMDX Price to Earnings CAGR:1Y: 21.55%2Y: -37.74%5Y: 0.00%10Y: 0.00%

TMDX - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

TMDX Price To Sales Ratio CAGR:1Y: -58.13%2Y: -47.29%5Y: -35.95%10Y: 0.00%

TMDX - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

TMDX Return on Capital Employed CAGR:1Y: -60.38%2Y: -1.09%5Y: 0.00%10Y: 0.00%

TMDX - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

TMDX Return on Invested Capital CAGR:1Y: -69.34%2Y: -14.59%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for TMDX

Based on past 7.4-year performance, here are TMDX growth metrics:

Share price CAGR of +19.6%
Dividend CAGR of +0%

Using TMDX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	TMDX (DRIP)	TMDX - No DRIP
Current Price	$84.07	$84.07
Start Shares	118.95	118.95
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	118.95	118.95
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$84.07	$84.07
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - TMDX

NOTE: Above numbers are our estimate based on TMDX's Dividend and Price CAGR over past 7.4 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

TransMedics Group, Inc. (TMDX) had its IPO on 2019-05-02, and is traded on NASDAQ stock exchange.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

TMDX website: https://www.transmedics.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — TMDX

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $84.07

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own TMDX? See every dividend it's paid you

Add your TMDX shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every TMDX dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

See my TMDX payments →

Free plan · up to 5 holdings